Terms: = Prostate cancer AND PWWP2A, Q8IYR3_HUMAN, Q96N64, MST101, MGC132770, KIAA1935, ENSG00000170234, 114825 AND Treatment
8009 results:
1. Increasing the radiation-induced cytotoxicity by silver nanoparticles and docetaxel in prostate cancer cells.
Hatami Zharabad S; Mohammadian M; Zohdi Aghdam R; Hassanzadeh Dizaj M; Behrouzkia Z
Mol Biol Rep; 2024 May; 51(1):633. PubMed ID: 38724835
[TBL] [Abstract] [Full Text] [Related]
2. CRISPR-Cas9 genome and long non-coding RNAs as a novel diagnostic index for prostate cancer therapy via liposomal-coated compounds.
Kadry MO; Abdel-Megeed RM
PLoS One; 2024; 19(5):e0302264. PubMed ID: 38723038
[TBL] [Abstract] [Full Text] [Related]
3. Dual-mode fluorescence and colorimetric smartphone-based sensing platform with oxidation-induced self-assembled nanoflowers for sarcosine detection.
Liu P; Sun Q; Gai Z; Yang F; Yang Y
Anal Chim Acta; 2024 Jun; 1306():342586. PubMed ID: 38692787
[TBL] [Abstract] [Full Text] [Related]
4. Spatial distribution of tumor-associated macrophages in an orthotopic prostate cancer mouse model.
Grayson KA; Greenlee JD; Himmel LE; Hapach LA; Reinhart-King CA; King MR
Pathol Oncol Res; 2024; 30():1611586. PubMed ID: 38689823
[TBL] [Abstract] [Full Text] [Related]
5. Antiproliferative and Apoptotic Effects of Murici (Byrsonima crassifolia (L.) Kunth and verbascifolia (L.) DC) and Taperebá (Spondias mombin L.) Extracts in Human prostate Cell Line (PC-3).
Amaral Muxfeldt Paim TOD; Simas NF; Abreu JP; Rosa L; Passos Barbosa Lima T; Teodoro AJ
Asian Pac J Cancer Prev; 2024 Apr; 25(4):1339-1347. PubMed ID: 38679995
[TBL] [Abstract] [Full Text] [Related]
6. Patient-Derived Xenograft Models for Translational prostate cancer Research and Drug Development.
Philp LK
Methods Mol Biol; 2024; 2806():153-185. PubMed ID: 38676802
[TBL] [Abstract] [Full Text] [Related]
7. Myeloid-derived suppressor cells attenuate the antitumor efficacy of radiopharmaceutical therapy using
Muralidhar A; Hernandez R; Morris ZS; Comas Rojas H; Bio Idrissou M; Weichert JP; McNeel DG
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38663936
[TBL] [Abstract] [Full Text] [Related]
8. Relationship between circulating FSH levels and body composition and bone health in patients with prostate cancer who undergo androgen deprivation therapy: The BLADE study.
Bergamini M; Dalla Volta A; Palumbo C; Zamboni S; Triggiani L; Zamparini M; Laganà M; Rinaudo L; Di Meo N; Caramella I; Bresciani R; Valcamonico F; Borghetti P; Guerini A; Farina D; Antonelli A; Simeone C; Mazziotti G; Berruti A
Elife; 2024 Apr; 13():. PubMed ID: 38656229
[TBL] [Abstract] [Full Text] [Related]
9. Developing a Novel Enzalutamide-Resistant prostate cancer Model via AR F877L Mutation in LNCaP Cells.
Wang R; Ma S; Xu N; Gan Y; Li P; Zhang J; Zhang Z; Gu Q; Xiang J
Curr Protoc; 2024 Apr; 4(4):e1033. PubMed ID: 38652202
[TBL] [Abstract] [Full Text] [Related]
10. Skin Changes in Suspected Lyme Disease.
Vržogić P; Perica A
Acta Dermatovenerol Croat; 2023 Dec; 31(4):225-228. PubMed ID: 38651851
[TBL] [Abstract] [Full Text] [Related]
11. Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [
Arbuznikova D; Klotsotyra A; Uhlmann L; Domogalla LC; Steinacker N; Mix M; Niedermann G; Spohn SKB; Freitag MT; Grosu AL; Meyer PT; Gratzke C; Eder M; Zamboglou C; Eder AC
Theranostics; 2024; 14(6):2560-2572. PubMed ID: 38646643
[TBL] [Abstract] [Full Text] [Related]
12. DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors.
Li X; Yao J; Qu C; Luo L; Li B; Zhang Y; Zhu Z; Qiu Y; Hua H
J Transl Med; 2024 Apr; 22(1):362. PubMed ID: 38632563
[TBL] [Abstract] [Full Text] [Related]
13. ELK3 destabilization by speckle-type POZ protein suppresses prostate cancer progression and docetaxel resistance.
Lee CJ; Lee H; Kim SR; Nam SB; Lee GE; Yang KE; Lee GJ; Chun SH; Kang HC; Lee JY; Lee HS; Cho SJ; Cho YY
Cell Death Dis; 2024 Apr; 15(4):274. PubMed ID: 38632244
[TBL] [Abstract] [Full Text] [Related]
14. Understanding and overcoming resistance to immunotherapy in genitourinary cancers.
Evans ST; Jani Y; Jansen CS; Yildirim A; Kalemoglu E; Bilen MA
Cancer Biol Ther; 2024 Dec; 25(1):2342599. PubMed ID: 38629578
[TBL] [Abstract] [Full Text] [Related]
15. Isolation, Identification and Chemical Modification of Bufadienolides from
Ye Q; Lin R; Chen Z; Li J; Zheng C
Molecules; 2024 Mar; 29(7):. PubMed ID: 38611850
[TBL] [Abstract] [Full Text] [Related]
16. Co-targeting SKP2 and KDM5B inhibits prostate cancer progression by abrogating AKT signaling with induction of senescence and apoptosis.
Brown LK; Kanagasabai T; Li G; Celada SI; Rumph JT; Adunyah SE; Stewart LV; Chen Z
Prostate; 2024 Jun; 84(9):877-887. PubMed ID: 38605532
[TBL] [Abstract] [Full Text] [Related]
17. The implications of single-cell RNA-seq analysis in prostate cancer: unraveling tumor heterogeneity, therapeutic implications and pathways towards personalized therapy.
Feng DC; Zhu WZ; Wang J; Li DX; Shi X; Xiong Q; You J; Han P; Qiu S; Wei Q; Yang L
Mil Med Res; 2024 Apr; 11(1):21. PubMed ID: 38605399
[TBL] [Abstract] [Full Text] [Related]
18. Blocking lipid synthesis induces DNA damage in prostate cancer and increases cell death caused by PARP inhibition.
Ribeiro CF; Rodrigues S; Bastos DC; Fanelli GN; Pakula H; Foiani M; Zadra G; Loda M
Sci Signal; 2024 Apr; 17(831):eadh1922. PubMed ID: 38593154
[TBL] [Abstract] [Full Text] [Related]
19. The protein composition of exosomes released by prostate cancer cells is distinctly regulated by androgen receptor-antagonists and -agonist to stimulate growth of target cells.
Atri Roozbahani G; Kokal-Ribaudo M; Heidari Horestani M; Pungsrinont T; Baniahmad A
Cell Commun Signal; 2024 Apr; 22(1):219. PubMed ID: 38589887
[TBL] [Abstract] [Full Text] [Related]
20. Overcoming statin resistance in prostate cancer cells by targeting the 3-hydroxy-3-methylglutaryl-CoA-reductase.
Göbel A; Pählig S; Motz A; Breining D; Traikov S; Hofbauer LC; Rachner TD
Biochem Biophys Res Commun; 2024 May; 710():149841. PubMed ID: 38588613
[TBL] [Abstract] [Full Text] [Related]
[Next]
